Outcome of the Board Meeting held on 12.11.2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.5 pts more than Nifty Microcap 250 and 1.6 pts more than its Healthcare Services peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The board approved unaudited standalone and consolidated results for Q2 and H1 FY26 (ended 30 September 2025). On a standalone basis, Q2 revenue rose modestly to Rs 1,043.17 lakhs from Rs 1,030.19 lakhs a year ago, but the company swung to a small loss of Rs 8.54 lakhs versus a profit of Rs 14.99 lakhs earlier. For the half-year, standalone revenue fell about 18% to Rs 1,864.74 lakhs and the company reported a loss of Rs 224.54 lakhs against a profit of Rs 175.07 lakhs in H1 FY25. Consolidated results also turned negative with a half-year loss of Rs 320.94 lakhs on revenue of Rs 2,117.86 lakhs. Short-term borrowings jumped sharply (standalone current borrowings nearly quadrupled to Rs 879.57 lakhs), and consolidated operating cash flow turned negative at Rs -194.44 lakhs. The statutory auditor issued an unmodified (clean) limited review report.
Negative for shareholders — the company has slipped from profit to loss both quarterly and half-yearly, revenue has shrunk on a half-year basis, leverage has risen, and consolidated operating cash flow has turned negative, suggesting pressure on near-term profitability and liquidity despite a clean auditor review.